302 related articles for article (PubMed ID: 27186130)
1. Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma.
Cucchi D; Occhione MA; Gulino A; De Smaele E
J Exp Pharmacol; 2012; 4():173-85. PubMed ID: 27186130
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
5. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
[TBL] [Abstract][Full Text] [Related]
6. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.
Basset-Seguin N; Sharpe HJ; de Sauvage FJ
Mol Cancer Ther; 2015 Mar; 14(3):633-41. PubMed ID: 25585509
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma.
Aditya S; Rattan A
Indian Dermatol Online J; 2013 Oct; 4(4):365-8. PubMed ID: 24350028
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.
Pietrobono S; Stecca B
Cells; 2018 Dec; 7(12):. PubMed ID: 30558232
[TBL] [Abstract][Full Text] [Related]
12. Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response.
Gambini D; Passoni E; Nazzaro G; Beltramini G; Tomasello G; Ghidini M; Kuhn E; Garrone O
Front Med (Lausanne); 2022; 9():893063. PubMed ID: 35775005
[TBL] [Abstract][Full Text] [Related]
13. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.
Doan HQ; Silapunt S; Migden MR
Onco Targets Ther; 2016; 9():5671-5678. PubMed ID: 27695345
[TBL] [Abstract][Full Text] [Related]
14. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
15. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.
Brancaccio G; Pea F; Moscarella E; Argenziano G
Front Oncol; 2020; 10():582866. PubMed ID: 33194718
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma.
Sternberg C; Gruber W; Eberl M; Tesanovic S; Stadler M; Elmer DP; Schlederer M; Grund S; Roos S; Wolff F; Kaur S; Mangelberger D; Lehrach H; Hache H; Wierling C; Laimer J; Lackner P; Wiederstein M; Kasper M; Risch A; Petzelbauer P; Moriggl R; Kenner L; Aberger F
Int J Cancer; 2018 Dec; 143(11):2943-2954. PubMed ID: 29987839
[TBL] [Abstract][Full Text] [Related]
17. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
18. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model.
Lauressergues E; Heusler P; Lestienne F; Troulier D; Rauly-Lestienne I; Tourette A; Ailhaud MC; Cathala C; Tardif S; Denais-Laliève D; Calmettes MT; Degryse AD; Dumoulin A; De Vries L; Cussac D
Pharmacol Res Perspect; 2016 Apr; 4(2):e00214. PubMed ID: 27069629
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know.
Alkeraye SS; Alhammad GA; Binkhonain FK
Cutis; 2022 Sep; 110(3):155-158. PubMed ID: 36446122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
